Outsourcing

Articles

An effective data structure and simple communication between production, logistics, and sales are essential for delivering this level of accountability, traceability, and security.

Serialization: Reducing Counterfeit Drugs and Increasing Sales

Investments, biologics, and the impact of COVID-19 will continue to shape the bio/pharmaceutical outsourcing industry for the near term.

CMOs and CDMOs Adjust to Pandemic Response and Beyond

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

There are some key questions that should be asked by both the sponsor company and the outsourcing partner before undertaking a method development project.

Picking the Perfect Method Development Partner

Craig A. Steger is SVP–Life Sciences at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

Thomas J. Joyce is Associate at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

Oded Ben-Joseph, PhD, is Managing Director, at Outcome Capital LLC, 99 High St., Suite 2900, Boston MA.

The CRO market will see greater consolidation by both financial buyers looking to consolidate smaller players and larger CRO players wanting to expand into value-added specialty service areas.

Pharma Services Sector Poised for Continued Growth and Consolidation

AMRI reinforces positioning as a CDMO with name change and acquires the formulation and fill/finish company, Integrity Bio, and biologics company, LakePharma.

AMRI Changes Name to Curia and Acquires Integrity Bio and LakePharma

UltraBurst has a high disintegration speed, which is for all market segments, from prescriptions to nutraceuticals.

SPI Pharma Introduces Platform for Orally Disintegrating Tablets

Purisys is now certified for ISO 17025 for testing and calibration laboratories and ISO 17034 for reference material producers

Purisys Adds ISO Certifications 

CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.

Balancing Pressing Priorities

The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.

Pinteon and Lonza Extend Collaboration for Manufacturing Antibody Therapeutic

Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.

Contract Manufacturing, General